Article Information
- Received June 20, 2016
- Revision received October 7, 2016
- Accepted October 14, 2016
- First published December 7, 2016.
- Version of record published December 7, 2016.
Author Information
Author contributions
Author contributions: W.L. and S.M.P. designed research; W.L., L.Z., M.J.C., B.B., M.P., M.Y.W., T.W., and F.Y. performed research; W.L., M.J.C., D.S., S.M.K., R.G.C., and S.M.P. contributed unpublished reagents/analytic tools; W.L. and S.M.P. analyzed data; W.L. and S.M.P. wrote the paper.
Disclosures
- Received June 20, 2016.
- Revision received October 7, 2016.
- Accepted October 14, 2016.
This work was supported by Appel Alzheimer's Research Institute and Alzheimer's Drug Discovery Foundation. We thank Maria Chiuchiolo, Caroline Ferreira and Yihharn Hwang for help with the studies. We thank Todd Carter and Dinah Sah for constructive comments and suggestions on the manuscript.
The authors declare no competing financial interests. However, the authors note that work was performed at Weill Cornell Medical College and a patent application for the use of AAV-vectored anti-tau monoclonal antibodies has been submitted by Weill Cornell. W.L. and S.M.P. are currently employees of Voyager Therapeutics, a CNS gene therapy company working on AAV vectors to deliver monoclonal antibodies to the CNS.
- Correspondence should be addressed to Steven M. Paul, MD, Voyager Therapeutics, 75 Sidney Street, Cambridge, MA 02139. Steve{at}vygr.com
Online Impact